Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401733 | 0.88 | HTT (0.43) | HTTGAAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12401538 | 0.82 | SMN1; SMN2 (0.36) | GAASMN1; SMN2 | |
| SCHEMBL12401540 | 0.82 | SMN1; SMN2 (0.36) | GAASMN1; SMN2 | |
| SCHEMBL12401717 | 0.79 | SMN1; SMN2 (0.43) | GAAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12401672 | 0.78 | SMN1; SMN2 (0.45) | GAAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14943449 | 0.74 | SMN1; SMN2 (0.46) | HTTGAAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12571970 | 0.71 | ALDH1A1 (0.49) | HTTGAAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12401663 | 0.71 | MME (0.45) | LMNA | |
| SCHEMBL12401535 | 0.70 | CTSK (0.36) | — | |
| SCHEMBL12401532 | 0.70 | CTSK (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | HTT 3023/4885GAA 773/4885MAPK1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.